Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

Linda Winston decided after over two decades being a patient dealing with Crohn’s disease, she wanted to become an advocate to help others contending with the condition. She is currently serving as ...

The Food and Drug Administration (FDA) has approved a new presentation of Selarsdi ™ (ustekinumab-aekn), a biosimilar to Stelara ® (ustekinumab), expanding the product’s indications to include ...

Dysphagia, or difficulty swallowing, is one such symptom that can be particularly alarming. Here’s what you can do if you ...

While Crohn’s disease is a lifelong condition, it doesn’t have to define your life. It can be managed with medication, mental ...